Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
News|Articles|August 1, 2025
OncLive’s July Roundup of Key FDA Approvals in Oncology: 4 Decisions to Know
Author(s)OncLive Staff
Fact checked by: Kristi Rosa
Here is your guide to all therapeutic options that were approved by the FDA in July 2025 spanning tumor types.
Advertisement
Advertisement
Below is your guide to all the oncologic therapeutic options approved by the FDA in July 2025. The roundup provides everything you need to know, right at your fingertips—all the topline data that supported the decisions and expert insights contextualizing what they mean for clinical practice.
Related to this article
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
The top 5 OncLive TV videos of the week cover insights in essential thrombocythemia, CML, pancreatic cancer, myelofibrosis, and chronic neutropenia.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
The conditional approval of fanregratinib is supported by pivotal phase 2 data showing a 42.5% objective response rate in pretreated FGFR2-altered intrahepatic cholangiocarcinoma.
Advertisement
Advertisement